TY - JOUR
T1 - Adjuvant Inhaled Corticosteroids in Community-Acquired Pneumonia
T2 - A Review Article
AU - Kukhon, Faeq R.
AU - Festic, Emir
PY - 2021/5/23
Y1 - 2021/5/23
N2 - Community-acquired pneumonia is still a major cause of morbidity and mortality worldwide. Since the inflammatory response induced by the immune system is often a major contributor to the lung injury, it becomes reasonable to assess the potential benefit of anti-inflammatory agents in treating community-acquired pneumonia. The role of corticosteroids as adjunct anti-inflammatory agents in treating community-acquired pneumonia is still controversial. Several studies have assessed the benefit of their use in patients with community-acquired pneumonia. In most of those studies, the route of corticosteroids administration was systemic. The aim of this article is to provide a concise review of the role of corticosteroids in treating community-acquired pneumonia when administered via inhalational route, with the potential benefit of avoiding systemic side effects of corticosteroids while exerting the same anti-inflammatory effects on the lungs. Conclusion: the use of inhaled corticosteroids may be of benefit in certain patient subsets with community-acquired pneumonia. Further randomized controlled trials are needed for better determination of such patient subsets.
AB - Community-acquired pneumonia is still a major cause of morbidity and mortality worldwide. Since the inflammatory response induced by the immune system is often a major contributor to the lung injury, it becomes reasonable to assess the potential benefit of anti-inflammatory agents in treating community-acquired pneumonia. The role of corticosteroids as adjunct anti-inflammatory agents in treating community-acquired pneumonia is still controversial. Several studies have assessed the benefit of their use in patients with community-acquired pneumonia. In most of those studies, the route of corticosteroids administration was systemic. The aim of this article is to provide a concise review of the role of corticosteroids in treating community-acquired pneumonia when administered via inhalational route, with the potential benefit of avoiding systemic side effects of corticosteroids while exerting the same anti-inflammatory effects on the lungs. Conclusion: the use of inhaled corticosteroids may be of benefit in certain patient subsets with community-acquired pneumonia. Further randomized controlled trials are needed for better determination of such patient subsets.
KW - community-acquired pneumonia
KW - inhaled corticosteroids
KW - long-acting beta agonists
KW - systemic corticosteroids
UR - http://www.scopus.com/inward/record.url?scp=85149160055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149160055&partnerID=8YFLogxK
U2 - 10.3390/medsci9020034
DO - 10.3390/medsci9020034
M3 - Review article
C2 - 34071031
AN - SCOPUS:85149160055
SN - 2076-3271
VL - 9
JO - Medical sciences (Basel, Switzerland)
JF - Medical sciences (Basel, Switzerland)
IS - 2
ER -